ArticleJournal of clinical biochemistry and nutrition2009
Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication.
Article in Journal of clinical biochemistry and nutrition, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Trial
- Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2013Trial
- Synonymous codon-optimized multiplex qPCR for simultaneous detection ofJournal of clinical microbiology · 2026Article
- Levofloxacin and Rifampin Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Development and validation of next-generation sequencing panel for personalizedFrontiers in cellular and infection microbiology · 2024Article
- Newer, Older, and Alternative Agents for the Eradication ofAntibiotics (Basel, Switzerland) · 2023Review
- Development of apigenin loaded gastroretentive microsponge for the targeting ofSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.Clinical microbiology reviews · 2022Review
- Sitafloxacin for Third-LineJournal of clinical medicine · 2021Review
- The Potential Benefits of Vonoprazan asPharmaceuticals (Basel, Switzerland) · 2020Review
- Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance ofAntibiotics (Basel, Switzerland) · 2020Article
- World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.Journal of gastroenterology · 2018Review
- Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of Helicobacter pylori: a series of six patients.Rheumatology international · 2018Article
- Microarray-Based Detection and Clinical Evaluation forBioMed research international · 2018Article
- Effects of patient age and choice of antisecretory agent on success of eradication therapy forJournal of clinical biochemistry and nutrition · 2017Article
- Review article: the global emergence of Helicobacter pylori antibiotic resistance.Alimentary pharmacology & therapeutics · 2016Review
- Article
- Article
- Attempts to enhance the eradication rate of Helicobacter pylori infection.World journal of gastroenterology · 2014Review
- Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing.Frontiers in molecular biosciences · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, a standard third-line therapy for Helicobacter pylori (H. pylori) eradication remains to be established. Quinolones show good oral absorption, no major side effects, and marked activity against H. pylori. Several authors have studied quinolone-based third-line therapy and reported encouraging results, with the reported H. pylori cure rates ranging from 60% to 84%. Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs. We recently reported a significant difference in the eradication rate obtained between patients infected with gatifloxacin-susceptible and gatifloxacin-resistant H. pylori, suggesting that the selection of quinolones for third-line therapy should be based on the results of drug susceptibility testing. As other alternatives of third-line rescue therapies, rifabutin-based triple therapy, high-dose proton pump inhibitor/amoxicillin therapy and furazolidone-based therapy have been suggested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.